Mammalian Smaug1/Samd4a is an mRNA regulator involved in synapse plasticity and additional non-neuronal functions. Here we analyzed the expression of Smaug1/Samd4a variants and Smaug2/Samd4b in primary hippocampal neurons and non-neuronal cell lines. We found that multiple Smaug proteins are present in several mammalian cell lines, including a canonical full length Smaug1, a Smaug1 variant that lacks the third exon, termed DEIII, and Smaug2, the product of a highly homologous gene. These three major isoforms are expressed differentially along neuron development and form cytosolic bodies when transfected in cell lines. By using luciferase reporters, we found that the DEIII isoform, which lacks 10 amino acids in the sterile a motif involved in RNA binding, shows a RNA-binding capacity and repressor activity comparable to that of the full length Smaug1. These observations are an important groundwork for molecular studies of the Smaug posttranscriptional pathway, which is relevant to neuron development, mitochondrial function and muscle physiology in health and disease.
Introduction
In several cellular contexts, translational repression is linked to the formation of mRNA-silencing bodies, which are supramolecular aggregates that store mRNAs excluded from the translational pool together with repressor proteins. By definition, mRNA-silencing bodies can dissolve in response to specific stimuli, allowing the translation of specific transcripts. Stress granules (SGs) and Processing Bodies (PBs) are the best described mRNA-silencing bodies (reviewed in ref. 1) . SGs form transiently upon cellular stress. PBs instead, are ubiquitous foci that contain molecules involved in mRNA repression and decay.
We have previously described a specific type of neuronal mRNA-silencing body called S-foci, as they contain the repressor protein Smaug1/Samd4a. 2 More recently, we reported that the 5 0 -3 0 exoribonuclease XRN1 forms discrete aggregates, termed Synaptic XRN1-bodies (SXbodies) apparently also involved in translational regulation at the post-synapse. 3 Both S-foci and SX-bodies are different from PBs or SGs, respond differently to a number of synaptic stimuli and belong to a growing family of neuronal bodies that contributes to the fine tuning of protein synthesis at the post-synapse, which we termed SyAS foci. [2] [3] [4] Both XRN1 and Smaug are expressed also in non-neuronal cell types and here we used several mammalian cell lines to study the expression and localization of XRN1 and Smaug molecules in cytoplasmic bodies. We found that at least 3 Smaug1/2 isoforms and splicing variants are present in mammalian cell lines. In addition, these 3 major Smaug molecules aggregate in cytosolic bodies. A Smaug1 splicing variant lacking the exon III binds RNA and displays a repressor activity comparable to that of the full length canonical Smaug1. These observations help to establish the molecular groundwork for future research on the Smaug regulatory pathway, which affect a wide range of key functions including insect early development, mammalian synapse plasticity and mitochondrial biogenesis.
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Results and discussion
Two highly homologous genes encoding Smaug1/Samd4a and Smaug2/Samd4b are present in vertebrates, 9, 10 opening the question on target specificity, redundancy and regulation diversity. In addition, Smaug1 has an alternative splicing isoform that lacks the third exon (amino acids 239 to 327, NM_001161576), 11, 12 which we called DEIII.
The excision of this exon removes the first 10 amino acids of a conserved sterile a motif (SAM), which is involved in the binding to a specific RNA motif termed Smaug Recognition Element (SRE) 9, 10, 13 (Fig. 1A) . First, we investigate by RT-PCR the presence of transcripts encoding the full length Smaug1 (FL Smaug1) and the DEIII variant during hippocampal neuron maturation in vitro at day 4, 8, 12 and 14 after plating (Fig. 1B) . We found that the transcript encoding the DEIII variant was present all along neuron development in vitro at about constant levels, whereas the transcript encoding the full length molecule greatly increased at 12 DIV, when synaptogenesis is massively triggered. Relevantly, we have shown before that Smaug1 proteins are not detected in hippocampal neurons before synaptogenesis and Smaug1 protein levels increase at day 10 along with synapse markers. 2 The expression of Drosophila Smaug is regulated at the translational level, with a strong repression of dSmaug mRNA during oogenesis, 14 and our observations suggest a similar repression of Smaug1 DEIII transcripts before synaptogenesis that remains to be investigated. A minor expression of Smaug1 protein variants at early times during hippocampal development cannot be ruled out and its putative relevance remains unknown.
Next, we compared the expression of Smaug1 (full length and DEIII together) and Smaug2 by quantitative PCR in cultured neurons before (8 days) and after synaptogenesis (14 days), and we found that the expression of both Smaug1 and Smaug2 transcripts increased 4 times at this developmental time (Fig. 1C) . This is in accordance with previous work reporting that the presence of Smaug proteins increases dramatically during synaptogenesis.
2 Smaug1 knockdown leads to the accumulation of immature synapsis 2 and the presence of Smaug2 transcripts in developing hippocampal neurons suggests an additional role for Smaug2 in synapse formation or neuron maturation, which remains to be investigated. It was shown recently that Smaug2 protein, but not Smaug1, is expressed during embryonic cortical neurogenesis. Smaug2 forms a translational repression complex that helps precursor maintenance. 15 As in hippocampal neurons, Smaug1 is expressed later during the development of cortical neurons, and altogether these observations suggest that Smaug1 and 2 are important at different times during neuron differentiation and maturation.
In addition to its role in neuronal precursors and in mRNA regulation at the post-synapse, recent work indicates that Smaug functions beyond the CNS. Smaug molecules are involved in translation homeostasis in Myotonic Dystrophy Type 1 (DM1) models and affect several transcripts involved in mitochondrial function in both Drosophila and mammals. [5] [6] [7] We analyzed the expression of Smaug1/2 isoforms and variants in several mammalian cell lines by RT-PCR and found that the 3 major Smaug1/2 transcripts expressed in primary hippocampal neurons are also present in cell lines derived from bone (U2OS), embryonic renal (HEK293T) and nervous tissue (SH-SY5Y) ( Fig. 2A) . Quantitative analysis indicates that both the full length Smaug1 isoform and the DEIII mRNAs are expressed at comparable levels in HEK293T and U2OS cells exponentially growing. In turn, Smaug2 mRNA is expressed at higher levels than Smaug1 mRNA, a feature more pronounced in HEK293T than in U2OS (Fig. 2B) . Like the Drosophila counterpart, mammalian Smaug1 regulates SRE-containing messengers, as is the case of CamKII mRNA and of chimeric reporters carrying SREs present in the Drosophila nanos mRNA. 2, 10 We investigated the RNA binding ability of DEIII, which lacks 10 amino acids in the SAM domain involved in the binding to SREs, by performing RNA-pull down assays with luciferase reporters and constructs fused to SBP (streptavidin binding protein). First, we assessed the binding of full length Smaug1 to transcripts carrying or not 3 SREs (described in ref. 10 ). As expected, we found that the reporter carrying binding sites is significantly recovered in the Smaug1 pull down whereas the recovery of a luciferase reporter without binding sites was negligible (Fig. 2C, left panel) . We simultaneously tested the binding of the SRE-containing transcript to maltose binding protein (MBP), which does not bind RNA, and found that it was not significantly recovered in the pull down (Fig. 2C, left panel) . With this experimental design we assessed the binding of the SRE-containing reporter to DEIII fused to SBP and found that DEIII binds RNA with a strength similar to that of the full length protein (Fig. 2C, right panel) . Thus, the first 10 amino acids of the SAM domain are dispensable for binding to SREs reporters. Differences in the binding to endogenous transcripts remain to be investigated.
Binding does not directly imply repression and we investigated the repressor activity of DEIII. We assessed the repression by the full length molecule and by DEIII fused to ECFP or V5 in BHK or U2OS cells using luciferase-based reporters carrying 3 wild type or mutant SREs. As expected, in all cases full length Smaug1 leads to a repression of about 25-40 %, similarly to that reported in other mammalian cell types 10 ( Fig. 2D) . Also in Drosophila embryos the overexpression of Smaug leads to a very modest repression of SRE-containing transcripts. 16 The effect of the DEIII was simultaneously analyzed and we found that 2 different DEIII constructs downregulated the expression of SRE-containing luciferase reporters with a strength similar to that of the full length protein (Fig. 2D ) both in BHK and U2OS cells. In contrast, 2 different constructs lacking the SAM domain showed not repression (Fig 2D) . Different members of a given family of RNA-binding proteins may compete for their target mRNAs eliciting disparate effects 17 and differences in the deadenylation or decay triggered by the multiple mammalian Smaug isoforms cannot be discarded. In addition, the selectivity in the binding to endogenous transcripts remains to be investigated. For example, The CamKII mRNA is positively and negatively regulated by Smaug1 and additional factors 2, 18, 19 and mammalian nanos1 mRNA is regulated by Smaug2. 15 Whether the multiple Smaug 1/2 isoforms differentially affect the fate of their targets is an open question.
Finally, we investigated whether these previously uncharacterized mammalian Smaug1/2 variants form cytosolic bodies, as described before for the Drosophila molecule and for the full length mammalian Smaug1. 2, 5, 10, 20 We found that when transfected in cell lines, the 3 Smaug1/2 isoforms aggregate in discrete foci (Fig. 3A) . The fraction of cells showing cytosolic bodies was similar (59% § 8 for Smaug1-ECFP; 58% § 11 for DEIII-ECFP; and 49% § 11 for Smaug2-Myc). The number and size of the bodies was comparable in all cases and moreover, the 3 molecules colocalized in the same bodies when co-expressed in pairs: 98.8% § 1.3 of Smaug1-ECFP foci contained Smaug2-Myc and 98% § 1 of Smaug2-Myc contained Smaug1-ECFP (N of foci: 293); 98.8% § 1.3 of Smaug1-EYFP foci contained Smaug2-Myc and 98% § of Smaug2-Myc contained Smaug1-EYFP (N of foci: 230); 97.8% § 3.3 of Smaug1-EYFP foci contained DEIII-ECFP and 98.8% § 1.3 of DEIII-ECFP foci contained Smaug1-EYFP (N of foci: 312); 97.5% § 3 of Smaug1-V5 foci contained DEIII-ECFP and 99.5% § 2 of DEIII-ECFP foci contained Smaug1-V5 (N of foci: 187); finally 97.4% § 4 of Smaug2-Myc foci contained DEIII-ECFP and 98.8% § (Fig. 3B and unpublished data) . We also calculated the Pearson's correlation coefficient (PCC) 21 in at least 20 regions of interest (ROIs) randomly taken for each pair of constructs. On average, we found high correlation coefficients (0.71 § 0.06 for Smaug1-ECFP and Smaug2-Myc; 0.83 § 0.05 for Smaug1-EYFP and Smaug2-Myc; 0.82 § 0.08 for DEIII-ECFP and Smaug1-EYFP; 0.79 § 0.11 for DEIII-ECFP and Smaug1-V5; and 0.68 § 0.06 for DEIII-ECFP and Smaug2-Myc). It was recently reported that endogenous Smaug molecules form cytosolic bodies in HEK293Tcells 5 and cortical neuron precursors 15 and our results suggest similar aggregation mechanisms for all known Smaug variants. The possibility of multiple Smaug bodies with different stoichiometry and that may respond to different cellular cues to trigger specific responses remains to be investigated.
In neurons, Smaug1 and XRN1 form mRNA silencing bodies located at post-synapses and termed S-foci and SX-bodies, respectively. These bodies respond to a number of stimuli with distinct patterns.
3 XRN1 and Smaug also co-exist in cell lines, where XRN1 is mostly present in PBs. We investigated whether XRN1 and Smaug1 form different bodies in U2OS. We found that most Smaug1-ECFP, DEIII-ECFP and Smaug2-Myc bodies exclude endogenous XRN1, as previously described for neurons. 3 We found that 14.9% § 8.8 of Smaug1-ECFP foci contain XRN1; 11.5% § 8 of DEIII-ECFP foci contain XRN1; and 11.3% § 10.7 of Smaug2-Myc foci contain XRN1.This relatively low colocalization in bodies is consistent with the PCCs, which are 0.23 § 0.08 for Smaug1-ECFP and XRN1; 0.2 § 0.09 for DEIII-ECFP and XRN1; and 0.25 § 0.09 for Smaug2-Myc and XRN1.
Collectively, these observations indicate that the repertoire of Smaug repressors present in mammalian cells include at least 3 molecules, all them with comparable ability to aggregate. All mammalian Smaug isoforms and splicing variants described up to date are present in neurons and non-neuronal cell lines. Functional differences are expected to be discovered between the different Smaug proteins, related to their redundancy or specificity in the repression of different transcripts, and to their responses upon synapse activation or specific cellular stimuli. These observations help to stablish the molecular groundwork for future research on Smaug-mediated post-transcriptional control in mammals, which we anticipate will be highly relevant to multiple cellular process, as Smaug regulates thousands of different messengers and is linked to synapse plasticity, muscle physiology and mitochondrial function in health and disease. [5] [6] [7] 14, 16, 22, 23 
Materials and methods
Hippocampal cultures were prepared as described previously. 2, 3 All cell lines were obtained from the American Tissue Culture Collection and grown and maintained as The indicated constructs were co-transfected and endogenous XRN1 was stained with a specific antibody. XRN1 is present in foci (likely PBs), which are largely excluded from the Smaug1/2 bodies. Percentage of Smaug1/2 foci containing endogenous XRN1 is indicated for each construct.
indicated. Cell lines were transfected with Jet Prime (Polyplus Transfection) according to manufacturer's instructions. Most used constructs were previously described. 2, 10 pSmaug1-DEIII-ECFP was constructed by S.O.E. PCR using pSmaug1-ECFP as a template and the following primers: forward 5 0 -GCACAAGTACAAATGTTC-CAGCCTG-3 0 , reverse 5 0 -AGGCTGGAACATTTG-TACTTGTGCTG-3 0 . PCR product was inserted using HindIII/BamHI in pECFP-N1 plasmid.
SBP (streptavidin binding protein) constructs were obtained by subcloning Smaug1 or DEIII cDNA sequence from EGFP containing plasmids into a pT7-V5-SBP vector.
For RT-PCR and qRT-PCR, total RNA was isolated by using TRIzol reagent (Invitrogen). First-strand cDNA was synthesized from 1 mg of total RNA using a random hexamer and expand reverse transcriptase (Roche Diagnostics). The cDNA was used as a template for PCR or quantitative PCR. Quantitative PCR was performed using Syber Green reagent (Applied Biosystem) and the amount of total cDNA was analyzed using specific primers for rat b-actin.
Primers used in PCR were: rat full lenght Smaug1: for- 0 -AGCCTCATGAGTCAGGCACT -3 0 . RNA-binding was analyzed by RNA-pull down assay. Briefly, HEK293T cells were co-transfected with SBPtagged constructs and LUC-SREC plasmids. Cells were resuspended in lysis buffer (150 mM NaCl, 25 mM Tris pH7.4, 5 mM EDTA, 0.5 mM DTT, 1% NP40 and 5% glycerol) using mild sonication and RNPs were pulled down with streptavidin sepharose beads (GE Health Care Lifesciences). The total RNA from inputs and pull down fractions was isolated and reverse transcribed. The cDNA was treated with DNase I and subsequently used for realtime PCR analysis of luciferase transcript using specific primers forward 5 0 -CCAGGGATTTCAGTCGATGT-3 0 , reverse 5 0 -AATCTCACGCAGGCAGTTCT-3 0 . Luciferase assays were performed as previously described. 10 Immunofluorescence of cultured cells was performed after fixation, permeabilization, and blocking as usual. 2, 3, 24, 25 Primary rabbit anti-XRN1 (Bethyl Laboratories) and rabbit anti-Myc (Cell Signaling), were diluted 1:100 and 1:200 respectively.
Pearson's correlation coefficients were calculated in random ROIs, using the Coloc2 plug-in of the Fiji (ImageJ) Software. 
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